LLY
Bearish signalScored 2026-09-06 Drivers: Congress, fundamentals. Insiders: neutral. Moteurs : Congrès, fondamentaux. Initiés : neutre.
Research, not advice.
À propos
Eli Lilly and Company
- Nom
- Eli Lilly and Company
- Secteur
- Healthcare
- Industrie
- Drug Manufacturers - General
- Bourse
- NYSE
- Capitalisation
- $1.23T
- Employés
- 50,000
- PDG
- David A. Ricks
- Site web
- https://www.lilly.com
- Marché
- ABBVAMGNAZNJNJMRKNVO
Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity. In oncology, Eli Lilly offers a robust portfolio targeting various cancers. These include Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza, indicated for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal and various head and neck cancers; Retevmo, used in metastatic NSCLC, medullary thyroid, and other thyroid cancers; Tyvyt for relapsed or refractory classic Hodgkin's lymphoma and non-squamous NSCLC; and Verzenio, prescribed for HR+, HER2- metastatic breast cancer, node-positive, and early breast cancer. For autoimmune and inflammatory conditions, the company markets Olumiant for rheumatoid arthritis, and Taltz, which addresses plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Addressing neurological and pain management needs, Eli Lilly provides Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is available for migraine prevention and episodic cluster headaches, while Zyprexa treats schizophrenia, bipolar I disorder, and aids in bipolar maintenance. Other significant products include Bamlanivimab and etesevimab, along with Bebtelovimab, both developed for COVID-19. Cialis is offered for erectile dysfunction and benign prostatic hyperplasia, and Forteo is available for osteoporosis. Eli Lilly actively engages in strategic collaborations with numerous partners, including Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Established in 1876, Eli Lilly and Company maintains its corporate headquarters in Indianapolis, Indiana.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
Decouvert par les declarations du Congres
- Insiders
- —
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$10,008,170
Avg sell (VWAP, 90d window) $1,177.43 vs last close —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$10,008,170 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- —
- Last synced
-
2026-10-20 00:36:23
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-08-17 | Jonsson Patrik | Sell · S · 10b5-1 | 6,500 | $1,175.10 | $7,638,150 | Form 4 |
| 2026-08-10 | Zakrowski Donald A | Sell · S · 10b5-1 | 2,000 | $1,185.01 | $2,370,020 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
| Date | Member | Side | Amount range | Filing |
|---|---|---|---|---|
| 2026-09-04 | Ro Khanna | Buy | $1,001 - $15,000 | Filing |
| 2026-01-02 | Michael A. Rulli | Buy | $1,001 - $15,000 | Filing |
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2026-09-04 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2026-07-10 | Daniel Milton Newhouse | Sale (Partial) | $1,001 - $15,000 |
| 2026-07-01 | Michael Rulli | Sale | $1,001 - $15,000 |
| 2026-06-10 | Gilbert Cisneros | Purchase | $50,001 - $100,000 |
| 2026-06-02 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2026-04-14 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2026-04-08 | Elizabeth Pannill Fletcher | Sale | $1,001 - $15,000 |
| 2026-04-02 | Byron Donalds | Purchase | $1,001 - $15,000 |
| 2026-04-02 | Byron Donalds | Purchase | $1,001 - $15,000 |
| 2026-03-13 | Gilbert Cisneros | Sale (Partial) | $1,001 - $15,000 |
| 2026-02-26 | David Taylor | Purchase | $1,001 - $15,000 |
| 2026-02-09 | David Taylor | Sale (Full) | $1,001 - $15,000 |
| 2026-01-16 | David Taylor | Sale (Full) | $1,001 - $15,000 |
| 2026-01-02 | Michael Rulli | Purchase | $1,001 - $15,000 |
| 2025-12-18 | Julie Johnson | Sale (Full) | $1,001 - $15,000 |
| 2025-12-10 | David Taylor | Sale (Full) | $1,001 - $15,000 |
| 2025-12-02 | Michael Rulli | Sale | $1,001 - $15,000 |
| 2025-11-18 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2025-11-13 | Julie Johnson | Sale (Partial) | $1,001 - $15,000 |
| 2025-09-23 | Val Hoyle | Sale (Full) | $1,001 - $15,000 |
| 2025-08-26 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2025-08-14 | Julie Johnson | Sale (Partial) | $1,001 - $15,000 |
| 2025-08-14 | David Taylor | Purchase | $1,001 - $15,000 |
| 2025-08-14 | David Taylor | Purchase | $15,001 - $50,000 |
| 2025-07-16 | Lisa C. McClain | Sale (Full) | $1,001 - $15,000 |
| 2025-07-10 | Lisa C. McClain | Purchase | $1,001 - $15,000 |
| 2025-07-02 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2025-06-09 | Lisa C. McClain | Sale (Partial) | $1,001 - $15,000 |
| 2025-06-06 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2025-06-03 | Jonathan Jackson | Sale (Full) | $15,001 - $50,000 |
| 2025-05-30 | Gilbert Cisneros | Sale | $1,001 - $15,000 |
| 2025-05-21 | Jonathan Jackson | Sale (Full) | $1,001 - $15,000 |
| 2025-05-14 | Marjorie Taylor Greene | Purchase | $1,001 - $15,000 |
| 2025-05-13 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2025-05-12 | Jefferson Shreve | Sale (Full) | $100,001 - $250,000 |
| 2025-05-06 | Val Hoyle | Sale (Partial) | $1,001 - $15,000 |
| 2025-05-05 | Marjorie Taylor Greene | Purchase | $1,001 - $15,000 |
| 2025-05-01 | Josh Gottheimer | Purchase | $1,001 - $15,000 |
| 2025-04-23 | Jonathan Jackson | Purchase | $1,001 - $15,000 |
| 2025-04-21 | Jonathan Jackson | Purchase | $15,001 - $50,000 |
| 2025-04-21 | Bruce Westerman | Sale (Full) | $1,001 - $15,000 |
| 2025-04-11 | Daniel Milton Newhouse | Sale (Partial) | $1,001 - $15,000 |
| 2025-04-09 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2025-04-08 | Robert P. Bresnahan | Sale (Full) | $1,001 - $15,000 |
| 2025-04-07 | Julie Johnson | Sale (Full) | $1,001 - $15,000 |
| 2025-03-10 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2025-03-03 | Bruce Westerman | Purchase | $1,001 - $15,000 |
| 2025-02-19 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2025-01-21 | Marjorie Taylor Greene | Purchase | $1,001 - $15,000 |
| 2025-01-08 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2024-12-24 | Marjorie Taylor Greene | Purchase | $1,001 - $15,000 |
| 2024-12-18 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2024-12-16 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2024-12-13 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2024-12-12 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2024-12-11 | Lisa C. McClain | Purchase | $1,001 - $15,000 |
| 2024-12-11 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2024-12-10 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2024-12-09 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2024-11-19 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2024-11-14 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2024-11-08 | Greg Landsman | Sale (Full) | $15,001 - $50,000 |
| 2024-11-01 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2024-10-29 | Val Hoyle | Purchase | $1,001 - $15,000 |
| 2024-10-16 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2024-07-01 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2024-06-07 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2024-06-03 | Greg Landsman | Sale (Partial) | $1,001 - $15,000 |
| 2024-04-10 | Daniel Milton Newhouse | Sale (Full) | $1,001 - $15,000 |
| 2024-03-01 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2024-02-13 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2024-02-08 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2024-02-02 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-12-28 | Jared Moskowitz | Purchase | $1,001 - $15,000 |
| 2023-12-28 | Jared Moskowitz | Purchase | $1,001 - $15,000 |
| 2023-12-04 | John R. Curtis | Sale (Full) | $1,001 - $15,000 |
| 2023-11-16 | Josh Gottheimer | Purchase | $1,001 - $15,000 |
| 2023-11-13 | Josh Gottheimer | Purchase | $1,001 - $15,000 |
| 2023-11-03 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-10-24 | Greg Stanton | Sale (Full) | $1,001 - $15,000 |
| 2023-10-11 | Josh Gottheimer | Purchase | $1,001 - $15,000 |
| 2023-10-06 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-10-02 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-09-26 | Greg Stanton | Purchase | $1,001 - $15,000 |
| 2023-09-21 | Josh Gottheimer | Purchase | $1,001 - $15,000 |
| 2023-09-13 | John R. Curtis | Purchase | $1,001 - $15,000 |
| 2023-09-12 | Josh Gottheimer | Purchase | $1,001 - $15,000 |
| 2023-09-01 | Jared Moskowitz | Purchase | $1,001 - $15,000 |
| 2023-09-01 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-05-11 | Greg Landsman | Purchase | $1,001 - $15,000 |
| 2023-05-09 | Josh Gottheimer | Purchase | $1,001 - $15,000 |
| 2023-05-05 | Josh Gottheimer | Purchase | $1,001 - $15,000 |
| 2023-05-03 | Josh Gottheimer | Purchase | $1,001 - $15,000 |
| 2023-05-01 | Josh Gottheimer | Purchase | $1,001 - $15,000 |
| 2023-03-06 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2023-02-02 | Greg Landsman | Sale (Full) | $1,001 - $15,000 |
| 2023-01-18 | Greg Landsman | Purchase | $1,001 - $15,000 |
| 2022-08-05 | Daniel Milton Newhouse | Sale (Partial) | $1,001 - $15,000 |
| 2022-06-30 | Roger Williams | Purchase | $1,001 - $15,000 |
| 2022-03-08 | Daniel Milton Newhouse | Purchase | $1,001 - $15,000 |
Signal
Bearish signalScored 2026-09-06 Drivers: Congress, fundamentals. Insiders: neutral. Moteurs : Congrès, fondamentaux. Initiés : neutre.
LLY presents middling liquidity and fundamental trend scores (50/50), but the complete absence of any event-driven catalyst (score: 0) with near-zero confidence (0.1) removes any short-term trading edge.
The first sentence of the analysis written for LLY on 2026-09-06 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Unavailable or mixed. – Insider: neutral. All sales (≈ $10.0M) were pre-planned Rule 10b5-1 trades, excluded from the score. No open-market buys or discretionary sales. – Initiés : neutre. Toutes les ventes (≈ $10.0M) sont sous plan 10b5-1 préétabli, exclues du score. Aucun achat ni vente discrétionnaire.
- Congress Pulls against a bullish reading. STOCK Act sale disclosures outnumber purchases
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Supports a bullish reading. Current ratio 1.58 · operating margin 46%
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 83.0% | 81.3% | 79.2% | 76.8% | 74.2% | |
| Ebit Margin | 45.6% | 37.8% | 20.6% | 25.0% | 22.9% | |
| Ebitda Margin | 48.6% | 41.8% | 25.1% | 30.3% | 28.4% | |
| Operating Profit Margin | 45.6% | 37.8% | 31.6% | 30.3% | 28.0% | |
| Pretax Profit Margin | 39.5% | 28.2% | 19.2% | 23.8% | 21.7% | |
| Continuous Operations Profit Margin | 31.7% | 23.5% | 15.4% | 21.9% | 19.7% | |
| Net Profit Margin | 31.7% | 23.5% | 15.4% | 21.9% | 19.7% | |
| Bottom Line Profit Margin | 31.7% | 23.5% | 15.4% | 21.9% | 19.7% | |
| Current Ratio | 1.579 | 1.154 | 0.943 | 1.052 | 1.226 | |
| Quick Ratio | 1.189 | 0.886 | 0.731 | 0.801 | 0.968 | |
| Solvency Ratio | 0.263 | 0.192 | 0.127 | 0.201 | 0.180 | |
| Cash Ratio | 0.203 | 0.115 | 0.103 | 0.121 | 0.254 | |
| Price To Earnings Ratio | 46.583 | 65.646 | 99.986 | 55.683 | 47.217 | |
| Price To Earnings Growth Ratio | 0.484 | 0.645 | -8.877 | 4.524 | -4.927 | |
| Forward Price To Earnings Growth Ratio | 0.484 | 0.645 | -8.877 | 4.524 | -4.927 | |
| Price To Earnings Diluted Ratio | 46.827 | 65.927 | 100.503 | 55.683 | 47.217 | |
| Price To Earnings Diluted Growth Ratio | 0.488 | 0.647 | -8.575 | 4.524 | -4.927 | |
| Price To Book Ratio | 36.370 | 48.990 | 48.670 | 32.640 | 29.336 | |
| Price To Sales Ratio | 14.806 | 15.436 | 15.364 | 12.179 | 9.302 | |
| Price To Free Cash Flow Ratio | 107.564 | 184.907 | -166.328 | 75.562 | 48.894 | |
| Price To Operating Cash Flow Ratio | 57.400 | 78.847 | 123.645 | 45.825 | 35.762 | |
| Debt To Assets Ratio | 0.378 | 0.427 | 0.394 | 0.328 | 0.346 | |
| Debt To Equity Ratio | 1.602 | 2.371 | 2.342 | 1.525 | 1.880 | |
| Debt To Capital Ratio | 0.616 | 0.703 | 0.701 | 0.604 | 0.653 | |
| Long Term Debt To Capital Ratio | 0.606 | 0.668 | 0.630 | 0.581 | 0.631 | |
| Financial Leverage Ratio | 4.239 | 5.546 | 5.942 | 4.647 | 5.435 | |
| Working Capital Turnover Ratio | 5.264 | 32.209 | -101.878 | 13.287 | 6.758 | |
| Operating Cash Flow Ratio | 0.477 | 0.311 | 0.155 | 0.443 | 0.489 | |
| Operating Cash Flow Sales Ratio | 0.258 | 0.196 | 0.124 | 0.266 | 0.260 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.534 | 0.426 | -0.743 | 0.606 | 0.731 | |
| Debt Service Coverage Ratio | 10.946 | 2.834 | 0.981 | 4.419 | 3.977 | |
| Interest Coverage Ratio | 37.339 | 21.829 | 22.201 | 26.096 | 23.346 | |
| Short Term Operating Cash Flow Coverage Ratio | 10.283 | 1.723 | 0.614 | 5.053 | 4.788 | |
| Operating Cash Flow Coverage Ratio | 0.396 | 0.262 | 0.168 | 0.467 | 0.436 | |
| Capital Expenditure Coverage Ratio | 2.144 | 1.743 | 0.574 | 2.541 | 3.723 | |
| Dividend Paid And Capex Coverage Ratio | 1.271 | 0.905 | 0.370 | 1.163 | 1.454 | |
| Dividend Payout Ratio | 0.261 | 0.442 | 0.777 | 0.566 | 0.553 | |
| Enterprise Value Multiple | 31.565 | 38.584 | 63.805 | 41.774 | 34.376 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 83.0% | ▲1.7% | ▲4.1% |
| Ebit Margin | 45.6% | ▲7.7% | ▲15.2% |
| Ebitda Margin | 48.6% | ▲6.9% | ▲13.8% |
| Operating Profit Margin | 45.6% | ▲7.7% | ▲10.9% |
| Pretax Profit Margin | 39.5% | ▲11.3% | ▲13.0% |
| Continuous Operations Profit Margin | 31.7% | ▲8.2% | ▲9.2% |
| Net Profit Margin | 31.7% | ▲8.2% | ▲9.2% |
| Bottom Line Profit Margin | 31.7% | ▲8.2% | ▲9.2% |
| Current Ratio | 1.579 | ▲0.425 | ▲0.388 |
| Quick Ratio | 1.189 | ▲0.303 | ▲0.274 |
| Solvency Ratio | 0.263 | ▲0.072 | ▲0.071 |
| Cash Ratio | 0.203 | ▲0.088 | ▲0.044 |
| Price To Earnings Ratio | 46.583 | ▼-19.063 | ▼-16.440 |
| Price To Earnings Growth Ratio | 0.484 | ▼-0.161 | ▲2.115 |
| Forward Price To Earnings Growth Ratio | 0.484 | ▼-0.161 | ▲2.115 |
| Price To Earnings Diluted Ratio | 46.827 | ▼-19.099 | ▼-16.404 |
| Price To Earnings Diluted Growth Ratio | 0.488 | ▼-0.159 | ▲2.057 |
| Price To Book Ratio | 36.370 | ▼-12.620 | ▼-2.832 |
| Price To Sales Ratio | 14.806 | ▼-0.629 | ▲1.389 |
| Price To Free Cash Flow Ratio | 107.564 | ▼-77.343 | ▲57.444 |
| Price To Operating Cash Flow Ratio | 57.400 | ▼-21.447 | ▼-10.896 |
| Debt To Assets Ratio | 0.378 | ▼-0.050 | ▲0.003 |
| Debt To Equity Ratio | 1.602 | ▼-0.769 | ▼-0.342 |
| Debt To Capital Ratio | 0.616 | ▼-0.088 | ▼-0.040 |
| Long Term Debt To Capital Ratio | 0.606 | ▼-0.061 | ▼-0.017 |
| Financial Leverage Ratio | 4.239 | ▼-1.308 | ▼-0.923 |
| Working Capital Turnover Ratio | 5.264 | ▼-26.945 | ▲14.136 |
| Operating Cash Flow Ratio | 0.477 | ▲0.167 | ▲0.102 |
| Operating Cash Flow Sales Ratio | 0.258 | ▲0.062 | ▲0.037 |
| Free Cash Flow Operating Cash Flow Ratio | 0.534 | ▲0.107 | ▲0.223 |
| Debt Service Coverage Ratio | 10.946 | ▲8.111 | ▲6.314 |
| Interest Coverage Ratio | 37.339 | ▲15.510 | ▲11.177 |
| Short Term Operating Cash Flow Coverage Ratio | 10.283 | ▲8.560 | ▲5.791 |
| Operating Cash Flow Coverage Ratio | 0.396 | ▲0.134 | ▲0.050 |
| Capital Expenditure Coverage Ratio | 2.144 | ▲0.401 | ▼-0.001 |
| Dividend Paid And Capex Coverage Ratio | 1.271 | ▲0.366 | ▲0.238 |
| Dividend Payout Ratio | 0.261 | ▼-0.181 | ▼-0.259 |
| Enterprise Value Multiple | 31.566 | ▼-7.018 | ▼-10.456 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $965.06B | $695.27B | $524.27B | $347.61B | $263.42B | |
| Enterprise value | $1000.40B | $725.64B | $546.67B | $361.79B | $276.48B | |
| EV / Sales | 15.35x | 16.11x | 16.02x | 12.68x | 9.76x | |
| EV / Op. cash flow | 59.50x | 82.29x | 128.93x | 47.69x | 37.54x | |
| EV / Free cash flow | 111.50x | 192.99x | -173.44x | 78.64x | 51.32x | |
| EV / EBITDA | 31.57x | 38.58x | 63.80x | 41.77x | 34.38x | |
| Net debt / EBITDA | 1.11x | 1.61x | 2.62x | 1.64x | 1.62x | |
| Current ratio | 1.58x | 1.15x | 0.94x | 1.05x | 1.23x | |
| Income quality | 0.81x | 0.83x | 0.81x | 1.22x | 1.32x | |
| Graham number | $124 | $65 | $40 | $41 | $35 | |
| Graham net-net | -$63 | -$52 | -$43 | -$29 | -$29 | |
| Tax burden | 80.2% | 83.5% | 79.9% | 91.7% | 90.7% | |
| Interest burden | 86.6% | 74.4% | 93.1% | 95.4% | 94.8% | |
| Working capital | $20.40B | $4.36B | -$1.57B | $896.3M | $3.40B | |
| Invested capital | $57.49B | $33.40B | $23.19B | $22.32B | $23.97B | |
| Return on assets | 18.4% | 13.5% | 8.2% | 12.6% | 11.4% | |
| Operating ROA | 31.1% | 23.9% | 19.0% | 17.6% | 16.6% | |
| Return on tangible assets | 20.6% | 15.9% | 10.0% | 16.3% | 15.0% | |
| Return on equity | 77.8% | 74.6% | 48.6% | 58.6% | 62.2% | |
| Return on invested capital | 30.2% | 25.7% | 19.8% | 23.5% | 20.4% | |
| Return on capital employed | 38.4% | 33.9% | 29.4% | 26.7% | 23.5% | |
| Earnings yield | 2.1% | 1.5% | 1.0% | 1.8% | 2.1% | |
| Free cash flow yield | 0.9% | 0.5% | -0.6% | 1.3% | 2.0% | |
| Capex / Op. cash flow | 46.6% | 57.4% | 174.3% | 39.4% | 26.9% | |
| Capex / Depreciation | 392.6% | 286.3% | 484.0% | 196.1% | 127.8% | |
| Capex / Sales | 12.0% | 11.2% | 21.7% | 10.5% | 7.0% | |
| SG&A / Sales | 17.0% | 19.1% | 20.3% | 21.3% | 21.7% | |
| R&D / Sales | 20.5% | 24.4% | 27.3% | 25.2% | 24.5% | |
| Stock comp / Sales | 1.0% | 1.4% | 1.8% | 1.3% | 1.2% | |
| Intangibles / Total assets | 11.0% | 15.2% | 18.5% | 22.8% | 23.7% | |
| Days sales outstanding | 113d | 108d | 121d | 109d | 105d | |
| Days payables outstanding | 178d | 140d | 134d | 106d | 83d | |
| Operating cycle | 567d | 437d | 419d | 347d | 299d | |
| Cash conversion cycle | 389d | 297d | 285d | 240d | 215d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-10-19 Tech Stocks Rebound From Heavy Losses Before Big Earnings Reports; Apple, Lilly Eye Buy Points Tech stocks rebounded Monday following Friday''s heavy losses ahead of big earnings reports. Apple, Eli Lilly and Visa are near buy points.
- 2026-10-19 Prediction: Eli Lilly Stock Could Be a Long-Term Winner for Investors Eli Lilly just crushed earnings again and sits within striking distance of its all-time high, but a looming price war with Novo Nordisk and a dangerously concentrated revenue base raise real questions about how long the momentum holds.
- 2026-10-19 Eli Lilly Plans Pediatric Omvoh Expansion After Phase 3 Trial Win Drugmaker Eli Lilly and Co. (LLY, Financials) plans to seek wider clearance for Omvoh after a late-stage research showed the medicine might assist youngsters with
- 2026-10-19 Is Eli Lilly Stock a Buy Right Now? Eli Lilly (LLY -0.92%) is expanding access at lower realized prices while its margins continue to improve. That unusual combination could become even more important as manufacturing costs fall, retatrutide approaches a potential 2027 filing, and investors weigh whether the company''s valuation still leaves room for growth.
- 2026-10-19 The AI Trade Just Moved Into Your Bloodstream, and 4 Healthcare Stocks Are Winning Rate and energy headlines have kept the broad market jumpy, yet one sector keeps finding buyers. Healthcare has led on days when the S&P 500 slipped, and the Nasdaq Biotechnology Index has pushed to record highs.
- 2026-10-19 What a Mixed Midterm Result Could Mean for These 2 Health Care ETFs As the midterm election approaches, investors may try to anticipate how different potential outcomes could impact the market. After two years of unified control by the Republican party, polls and analysis are predicting a divided government, with at least one of the chambers of Congress controlled by Democrats beginning in 2027.
- 2026-10-19 Metis TechBio inks up to $1.1 billion deal with Eli Lilly for drug delivery tech Metis TechBio inks up to $1.1 billion deal with Eli Lilly for drug delivery tech
- 2026-10-19 Lilly''s Omvoh (mirikizumab-mrkz) meets primary endpoint of clinical remission and is the first IL-23p19 inhibitor to report one-year Phase 3 results in pediatric ulcerative colitis Building on Omvoh''s approved use and durable efficacy in adults, Lilly plans to submit these data to global regulators to support a potential label expansion for pediatric ulcerative colitis More than 80% of patients responded to Omvoh induction, and half of responders, ages 6 to 17, were in clinical remission at one year in Phase 3 SHINE-2 study In key secondary outcomes, 71.2% of patients who responded to Omvoh induction achieved symptomatic remission and 50% achieved corticosteroid-free clinical remission at one year without surgery INDIANAPOLIS, Oct. 19, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive late-breaking one-year results from the Phase 3 SHINE-2 study of Omvoh (mirikizumab-mrkz) in pediatric patients ages 6 to 17 with moderately to severely active ulcerative colitis (UC), including clinical, symptomatic and endoscopic outcomes. In the single-arm, open-label study, 81% of patients achieved clinical response to Omvoh induction at Week 12.
- 2026-10-19 Warren Buffett''s Bluntest Warning Yet -- and 3 Stocks Built to Survive It Buffett has warned about "gambling" in the market.
- 2026-10-18 Lilly to showcase advances across its oncology pipeline at the 2026 European Society for Medical Oncology (ESMO) Congress Lilly to showcase advances across its oncology pipeline at the 2026 European Society for Medical Oncology (ESMO) CongressPR NewswireINDIANAPOLIS, Oct. 18, 2026F